2026 September - 8 articles
Acute myeloid leukemia (AML) is predominantly a disease of older adults, with a median age at diagnosis of 68–72 years. Management in this population is complicated by adverse cytogenetic and molecular features, higher rates of secondary diseas...
Emperipolesis, a cell-in-cell phenomenon, involves a viable cell being transiently internalized within another cell’s cytoplasm from which it can exit without damaging either cell. In this report, we discuss the rarity of the emperipolesis of e...
Background/Objectives: Patients receiving allogeneic hematopoietic stem cell transplantation (alloHCT) for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are at high risk for severe disease and treatment-related complications and...
Background: Treatment strategies for myelodysplastic syndromes (MDS) range from supportive care to disease-modifying therapies, depending on risk stratification and patient characteristics. Hypomethylating agents (HMAs) remain the standard treatment...
Background: Multiple myeloma (MM) is a hematological malignancy characterized by systemic inflammation and frequent renal involvement. The C-reactive protein-to-albumin ratio (CAR) has emerged as a potential inflammation-based biomarker; however, its...
Background/Objectives: A complex karyotype (CK) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) is defined as the presence of three or more unrelated chromosomal abnormalities in the absence of defining core-binding factor transl...
Nutritional deterioration in adults with acute myeloid leukemia (AML) may be present at diagnosis and may evolve rapidly during intensive chemotherapy, lower-intensity treatment, and allogeneic hematopoietic cell transplantation (allo-HCT). This stru...
Pre-hospital use of whole blood is becoming increasingly prevalent in EMS and military medicine. Technologies to store, transport, warm up, and transfuse the blood are now available, and the outcome of whole blood transfusion seems to be superior to...
